NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer
Background High-dose radiotherapy (RT) is known to be immunogenic, but is rarely capable of driving clinically relevant abscopal antitumor immunity as monotherapy. RT is known to increase antigen presentation, type I/II interferon responses, and immune cell trafficking to irradiated tumors. Bempegal...
Main Authors: | Melissa J Kasiewicz, Michael J McNamara, Joshua M Walker, Annah S Rolig, Daniel C Rose, Ian F Hilgart-Martiszus |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e000464.full |
Similar Items
-
Correction: Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
by: Melissa J Kasiewicz, et al.
Published: (2020-06-01) -
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
by: Deborah Charych, et al.
Published: (2017-01-01) -
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
by: William Redmond, et al.
Published: (2020-11-01) -
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
by: Peter Kirk, et al.
Published: (2021-05-01) -
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
by: Jing Ye, et al.
Published: (2020-11-01)